<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611372</url>
  </required_header>
  <id_info>
    <org_study_id>SAHZJU_RBD</org_study_id>
    <nct_id>NCT05611372</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease</brief_title>
  <official_title>Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Nanjing Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Hangzhou Normal University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether a year of rasagiline may reduce the progression from idiopathic REM&#xD;
      sleep behavior disorder (RBD) to Parkinson's disease (PD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival time</measure>
    <time_frame>3 years after starting rasagiline treatment</time_frame>
    <description>Not diagnosed as any of the synucleinopathies (Parkinson's disease; dementia with lewy body; multiple system atrophy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Striatal dopaminergic innervation</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
    <description>Striatal binding ratio from DAT-Scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS-UPDRS-III</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MoCA</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAMA</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAMD</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBDQ-HK</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSQI</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDQ39</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCOPA-AUT</measure>
    <time_frame>0-3 years after starting rasagiline treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">732</enrollment>
  <condition>REM Sleep Behavior Disorder</condition>
  <condition>Parkinson Disease</condition>
  <condition>Synucleinopathies</condition>
  <arm_group>
    <arm_group_label>Early Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0-52 week: rasagiline 1 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0-26 week: palcebo 1mg/day 27-52 week: rasagiline 1mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <description>1 mg rasagiline</description>
    <arm_group_label>Delayed Intervention</arm_group_label>
    <arm_group_label>Early Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PSG confirmed RBD with subtle motor symptoms (4≤MDS-UPDRS-III≤10 at baseline)&#xD;
&#xD;
          -  no clinical diagnosis of Parkinson's disease or dementia at baseline&#xD;
&#xD;
          -  age 30-75&#xD;
&#xD;
          -  no concomitant or previous use of any other anti-parkinson medications&#xD;
&#xD;
          -  provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosed with secondary parkinsonism (eg., drug-induced, vascular, psychogenic)&#xD;
&#xD;
          -  secondary RBD (eg., drug-induced, immune-mediated)&#xD;
&#xD;
          -  nervous system comorbidities (eg., stroke, epilepsy, encephalitis)&#xD;
&#xD;
          -  severe psychiatric comorbidities&#xD;
&#xD;
          -  allergic to rasagiline&#xD;
&#xD;
          -  severe systemic diseases (eg., end-stage kidney disease, liver failure)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baorong Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, Zhejiang University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baorong Zhang, MD</last_name>
    <phone>86 13958167260</phone>
    <email>brzhang@zju.edu.cn</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 6, 2022</study_first_submitted>
  <study_first_submitted_qc>November 6, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 6, 2022</last_update_submitted>
  <last_update_submitted_qc>November 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>REM Sleep Behavior Disorder</mesh_term>
    <mesh_term>Synucleinopathies</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

